| Year |
Citation |
Score |
| 2020 |
Dorigo O, Fiset S, MacDonald LD, Bramhecha Y, Hrytsenko O, Dirk B, Rosu GN, Stanford M. DPX-Survivac, a novel T-cell immunotherapy, to induce robust T-cell responses in advanced ovarian cancer. Journal of Clinical Oncology. 38: 6-6. DOI: 10.1200/Jco.2020.38.5_Suppl.6 |
0.344 |
|
| 2020 |
Dorigo O, MacDonald LD, Schindler J, Bramhecha Y, Torrey H, Kaliaperumal V, Hrytsenko O, Dirk B, Patterson K, Stanford M, Fiset S. Infiltration of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA) leads to clinical responses in advanced recurrent ovarian cancer (OvCa). Journal of Clinical Oncology. 38: 6075-6075. DOI: 10.1200/Jco.2020.38.15_Suppl.6075 |
0.348 |
|
| 2019 |
Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, Krishnan V, Hatakeyama J, Dorigo O, Barkal LJ, Weissman IL. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. PMID 31367043 DOI: 10.1038/S41586-019-1456-0 |
0.315 |
|
| 2019 |
Möckl L, Pedram K, Roy AR, Krishnan V, Gustavsson AK, Dorigo O, Bertozzi CR, Moerner WE. Quantitative Super-Resolution Microscopy of the Mammalian Glycocalyx. Developmental Cell. PMID 31105009 DOI: 10.1016/J.Devcel.2019.04.035 |
0.309 |
|
| 2019 |
Malaker SA, Pedram K, Ferracane MJ, Bensing BA, Krishnan V, Pett C, Yu J, Woods EC, Kramer JR, Westerlind U, Dorigo O, Bertozzi CR. The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins. Proceedings of the National Academy of Sciences of the United States of America. PMID 30910957 DOI: 10.1073/Pnas.1813020116 |
0.312 |
|
| 2019 |
Natarajan S, Foreman KM, Soriano MI, Rossen NS, Shehade H, Fregoso DR, Eggold JT, Krishnan V, Dorigo O, Krieg AJ, Heilshorn SC, Sinha S, Fuh KC, Rankin EB. Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis. Cancer Research. PMID 30862717 DOI: 10.1158/0008-5472.Can-18-2616 |
0.353 |
|
| 2019 |
Tanyi JL, Dorigo O, Oza AM, Strauss JF, Pejovic T, Ghamande SA, Ghatage P, Villella JA, Fiset S, MacDonald LD, Hrytsenko O, Stanford M, Newton RC, Leopold L, Rosu GN. DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE1 trial): T cell responses and tumor infiltration correlate with tumor regression. Journal of Clinical Oncology. 37: 5576-5576. DOI: 10.1200/Jco.2019.37.15_Suppl.5576 |
0.334 |
|
| 2019 |
Natarajan S, Foreman K, Soriano M, Shehade H, Fregoso D, Eggold J, Rosen NS, Heilshorn S, Krieg AJ, Krishnan V, Dorigo O, Sinha S, Fuh KC, Rankin EB. Abstract TMIM-081: THE HYPOXIC TUMOR-MESOTHELIAL NICHE PROMOTES OVARIAN CANCER METASTASIS THROUGH COLLAGEN REMODELING Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Tmim-081 |
0.359 |
|
| 2019 |
Krishnan V, Tallapragada S, Schaar B, Chanana A, Rinker-Schaeffer C, Dorigo O. Abstract TMIM-076: OMENTAL MACROPHAGES REGULATE OVARIAN CANCER METASTATIC COLONIZATION THROUGH THE CCL6-CCR1 SIGNALING AXIS Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Tmim-076 |
0.369 |
|
| 2018 |
Gill NK, Ly C, Nyberg KD, Lee L, Qi D, Tofig B, Reis-Sobreiro M, Dorigo O, Rao J, Wiedemeyer R, Karlan B, Lawrenson K, Freeman MR, Damoiseaux R, Rowat AC. A scalable filtration method for high throughput screening based on cell deformability. Lab On a Chip. PMID 30566156 DOI: 10.1039/C8Lc00922H |
0.36 |
|
| 2018 |
Krishnan V, Schaar B, Tallapragada S, Dorigo O. Tumor associated macrophages in gynecologic cancers. Gynecologic Oncology. PMID 29395307 DOI: 10.1016/J.Ygyno.2018.01.014 |
0.31 |
|
| 2018 |
Schaar B, Krishnan V, Tallapragada S, Dorigo O. Cell-based immunotherapy in gynecologic malignancies. Current Opinion in Obstetrics & Gynecology. 30: 23-30. PMID 29227304 DOI: 10.1097/Gco.0000000000000433 |
0.348 |
|
| 2018 |
Dorigo O, Tanyi JL, Strauss J, Oza AM, Pejovic T, Ghatage P, Villella JA, Fiset S, MacDonald LD, Leopold L, Rosu GN. Clinical data from the DeCidE1 trial: Assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer. Journal of Clinical Oncology. 36: 5510-5510. DOI: 10.1200/Jco.2018.36.15_Suppl.5510 |
0.305 |
|
| 2018 |
Krishnan V, Raju PA, Vierkoetter K, Patel S, Youngyunpipatkul J, Tallapragada S, Schaar B, Folkins AK, Herzenberg LA, Dorigo O. Abstract 5074: Omentum immune microenvironment: Metastatic niche for ovarian cancer Cancer Research. 78: 5074-5074. DOI: 10.1158/1538-7445.Am2018-5074 |
0.35 |
|
| 2017 |
MacKay HJ, Levine DA, Bae-Jump VL, Bell DW, McAlpine JN, Santin A, Fleming GF, Mutch DG, Nephew KP, Wentzensen N, Goodfellow PJ, Dorigo O, Nijman HW, Broaddus R, Kohn EC. Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget. 8: 84579-84594. PMID 29137450 DOI: 10.18632/Oncotarget.19961 |
0.312 |
|
| 2017 |
He H, Chiu AC, Kanada M, Schaar BT, Krishnan V, Contag CH, Dorigo O. Imaging of Tumor-Associated Macrophages in a Transgenic Mouse Model of Orthotopic Ovarian Cancer. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 28233218 DOI: 10.1007/S11307-017-1061-2 |
0.339 |
|
| 2017 |
Odunsi K, Cristea MC, Dorigo O, Jazaeri AA, Slomovitz BM, Chagin K, Van Winkle E, Kari G, Iyengar M, Norry E, Bartlett-Pandite AN, Amado RG. A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891). Journal of Clinical Oncology. 35: TPS3094-TPS3094. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps3094 |
0.359 |
|
| 2017 |
Krishnan V, Schaar B, Rinker-Schaeffer C, Dorigo O. Abstract TMEM-028: OMENTAL MACROPHAGES REGULATE OVARIAN CANCER METASTATIC COLONIZATION Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Tmem-028 |
0.364 |
|
| 2016 |
Krishnan V, Berek JS, Dorigo O. Immunotherapy in ovarian cancer. Current Problems in Cancer. PMID 28169004 DOI: 10.1016/J.Currproblcancer.2016.11.003 |
0.32 |
|
| 2015 |
Qi D, Kaur Gill N, Santiskulvong C, Sifuentes J, Dorigo O, Rao J, Taylor-Harding B, Ruprecht Wiedemeyer W, Rowat AC. Screening cell mechanotype by parallel microfiltration. Scientific Reports. 5: 17595. PMID 26626154 DOI: 10.1038/Srep17595 |
0.361 |
|
| 2015 |
Chester C, Dorigo O, Berek JS, Kohrt H. Immunotherapeutic approaches to ovarian cancer treatment. Journal For Immunotherapy of Cancer. 3: 7. PMID 25806106 DOI: 10.1186/S40425-015-0051-7 |
0.338 |
|
| 2015 |
Elvin JA, Bailey M, Carneiro BA, Ali SM, Vergilio J, Palma NA, Chmielecki J, Frampton GM, Lipson D, Stephens P, Miller VA, Johnson ML, Giles FJ, Ross JS, Dorigo O. Comprehensive genomic profiling (CGP) of cervical squamous cell carcinoma (cSCC) to identifiy targeted therapy options. Journal of Clinical Oncology. 33: 5602-5602. DOI: 10.1200/Jco.2015.33.15_Suppl.5602 |
0.325 |
|
| 2015 |
Moughon D, He H, Schokrpur S, Jiang Z, Yaqoob M, David J, Iruela-Arispe L, Dorigo O, Wu L. Abstract A48: M2 macrophage inhibition reverses vascular leaks that cause malignant ascites in late-stage epithelial ovarian cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-A48 |
0.336 |
|
| 2015 |
He HM, Yu FB, Quake SR, Dorigo O. Abstract 3202: Single cell analysis of ascites macrophages in ovarian cancer Cancer Research. 75: 3202-3202. DOI: 10.1158/1538-7445.Am2015-3202 |
0.376 |
|
| 2015 |
Wiedemeyer W, Qi D, Gill NK, Santiskulvong C, Dorigo O, Rao J, Taylor-Harding B, Rowat AC. Abstract 226: Parallel microfiltration (PMF): A novel method to screen cell mechanotype Cancer Research. 75: 226-226. DOI: 10.1158/1538-7445.Am2015-226 |
0.393 |
|
| 2014 |
Sharma S, Santiskulvong C, Rao J, Gimzewski JK, Dorigo O. The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells. Integrative Biology : Quantitative Biosciences From Nano to Macro. 6: 611-7. PMID 24718685 DOI: 10.1039/C3Ib40246K |
0.338 |
|
| 2013 |
Santiskulvong C, Sharma S, Bentolila L, Rao JY, Gimzewski J, Dorigo O. Abstract 2122: The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells. Cancer Research. 73: 2122-2122. DOI: 10.1158/1538-7445.Am2013-2122 |
0.334 |
|
| 2012 |
Stoll LM, Parvataneni R, Johnson MW, Gui D, Dorigo O, Sullivan P. Solid pseudopapillary neoplasm, pancreas type, presenting as a primary ovarian neoplasm. Human Pathology. 43: 1339-43. PMID 22534259 DOI: 10.1016/J.Humpath.2011.12.018 |
0.305 |
|
| 2012 |
Sullivan PS, Maresh EL, Seligson DB, Habeeb O, Wadehra M, Goodglick L, Dorigo O. Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 25: 1140-8. PMID 22460811 DOI: 10.1038/Modpathol.2012.64 |
0.329 |
|
| 2012 |
Karam A, Dorigo O. MMPs in ovarian cancer as therapeutic targets. Anti-Cancer Agents in Medicinal Chemistry. 12: 764-72. PMID 22292752 DOI: 10.2174/187152012802650174 |
0.318 |
|
| 2012 |
Sharma S, Santiskulvong C, Bentolila LA, Rao J, Dorigo O, Gimzewski JK. Correlative nanomechanical profiling with super-resolution F-actin imaging reveals novel insights into mechanisms of cisplatin resistance in ovarian cancer cells. Nanomedicine : Nanotechnology, Biology, and Medicine. 8: 757-66. PMID 22024198 DOI: 10.1016/J.Nano.2011.09.015 |
0.33 |
|
| 2012 |
Santiskulvong C, Eng C, Wang DT, Lung WY, Zabih S, Koya RC, Dorigo O. Abstract 836: Insulin-like growth factor-I receptor (IGF-IR) dowregulation in cisplatin-resistant human ovarian cancer cells Cancer Research. 72: 836-836. DOI: 10.1158/1538-7445.Am2012-836 |
0.333 |
|
| 2012 |
Topka CR, ElMasri WM, Magyar CE, Song M, Dorigo O. Abstract 1862: NY-ESO-1 and clinicopathological features in ovarian cancer Cancer Research. 72: 1862-1862. DOI: 10.1158/1538-7445.Am2012-1862 |
0.345 |
|
| 2011 |
Penner K, Wadehra M, Steinhardt A, Hogue C, Cass I, Walsh C, Holschneider C, Braun J, Dorigo O. Abstract 3157: Expression of progesterone receptor and p4EBP1 as molecular predictors of response to progestin treatment in endometrial adenocarcinoma and complex atypical hyperplasia Cancer Research. 71: 3157-3157. DOI: 10.1158/1538-7445.Am2011-3157 |
0.314 |
|
| 2011 |
Dorigo O, Moughon DL, Masri WE, Lily W. Abstract C183: Inhibition of CSF1 receptor signaling targets tumor associated macrophages in a murine ovarian cancer model. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C183 |
0.383 |
|
| 2010 |
Karam AK, Santiskulvong C, Fekete M, Zabih S, Eng C, Dorigo O. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken, N.J.). 67: 535-44. PMID 20607860 DOI: 10.1002/Cm.20465 |
0.331 |
|
| 2010 |
Kim A, Gabayan V, Dorigo O, Ganz T, Rivera S. Two Mouse Models Illustrate Different Mechanisms of Anemia of Cancer Blood. 116: 2034-2034. DOI: 10.1182/Blood.V116.21.2034.2034 |
0.304 |
|
| 2009 |
Gallaher SD, Gil JS, Dorigo O, Berk AJ. Robust in vivo transduction of a genetically stable Epstein-Barr virus episome to hepatocytes in mice by a hybrid viral vector. Journal of Virology. 83: 3249-57. PMID 19158239 DOI: 10.1128/Jvi.01721-08 |
0.764 |
|
| 2006 |
Schwarz J, Schwarz SC, Dorigo O, Stützer A, Wegner F, Labarca C, Deshpande P, Gil JS, Berk AJ, Lester HA. Enhanced expression of hypersensitive alpha4* nAChR in adult mice increases the loss of midbrain dopaminergic neurons. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 935-46. PMID 16675851 DOI: 10.1096/Fj.05-5497Com |
0.708 |
|
| 2005 |
Gil JS, Gallaher SD, Dorigo O, Berk AJ. 890. Development of a Single Vector System for Gene Delivery Via Hybrid Helper Dependent Adenovirus - Epstein-Barr Virus Vector for Long Term Persistance Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.433 |
0.754 |
|
| 2005 |
Gallaher SD, Gil JS, Dorigo O, Berk AJ. 874. Long-Term Transgene Expression In Vivo from a Helper Dependent Adenovirus|[mdash]|Epstein-Barr Virus Hybrid Vector Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.417 |
0.769 |
|
| 2004 |
Dorigo O, Gil JS, Gallaher SD, Tan BT, Castro MG, Lowenstein PR, Calos MP, Berk AJ. Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. Journal of Virology. 78: 6556-66. PMID 15163748 DOI: 10.1128/Jvi.78.12.6556-6566.2004 |
0.765 |
|
| 2004 |
Gallaher SD, Gil JS, Dorigo O, Berk AJ. 773. Non-Invasive In Vivo Detection of Episomes Delivered to Mouse Hepatocytes by a Helper Dependent Adenovirus- Epstein-Barr Virus Hybrid Vector System Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.697 |
0.767 |
|
| 2003 |
Berek JS, Dorigo O, Schultes B, Nicodemus C. Specific keynote: immunological therapy for ovarian cancer. Gynecologic Oncology. 88: S105-9; discussion S. PMID 12586097 DOI: 10.1006/Gyno.2002.6695 |
0.3 |
|
| 2002 |
Shawler DL, Bartholomew RM, Garrett MA, Trauger RJ, Dorigo O, Van Beveren C, Marchese A, Ferre F, Duffy C, Carlo DJ, Sherman LA, Gold DP, Sobol RE. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. Clinical and Experimental Immunology. 129: 99-106. PMID 12100028 DOI: 10.1046/J.1365-2249.2002.01863.X |
0.34 |
|
| 1998 |
Dorigo O, Shawler DL, Royston I, Sobol RE, Berek JS, Fakhrai H. Combination of transforming growth factor β antisense and interleukin- 2 gene therapy in the murine ovarian teratoma model Gynecologic Oncology. 71: 204-210. PMID 9826461 DOI: 10.1006/Gyno.1998.5151 |
0.331 |
|
| 1998 |
Dorigo O, Turla ST, Lebedeva S, Gjerset RA. Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function Journal of Neurosurgery. 88: 535-540. PMID 9488309 DOI: 10.3171/Jns.1998.88.3.0535 |
0.358 |
|
| 1997 |
Dorigo O, Berek JS. Gene therapy for ovarian cancer: Development of novel treatment strategies International Journal of Gynecological Cancer. 7: 1-13. PMID 12795798 DOI: 10.1046/J.1525-1438.1997.00411.X |
0.37 |
|
| 1997 |
Fakhrai H, Shawler DL, Van Beveren C, Lin H, Dorigo O, Solomon MJ, Gjerset RA, Smith L, Bartholomew RM, Boggiano CA, Gold DP, Sobol RE. Construction and characterization of retroviral vectors for interleukin- 2 gene therapy Journal of Immunotherapy. 20: 437-448. PMID 9409449 DOI: 10.1097/00002371-199711000-00003 |
0.331 |
|
| 1996 |
Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy Proceedings of the National Academy of Sciences of the United States of America. 93: 2909-2914. PMID 8610141 DOI: 10.1073/Pnas.93.7.2909 |
0.346 |
|
| 1995 |
Gjerset RA, Fakhrai H, Shawler DL, Turla S, Dorigo O, Grover-Bardwick A, Mercola D, Wen SF, Collins H, Lin H, Garcia MV, Kruse CA, Royston I, Sobol RE. Characterization of a new human glioblastoma cell line that expresses mutant P53 and lacks activation of the PDGF pathway In Vitro Cellular &Amp; Developmental Biology - Animal: Journal of the Society For in Vitro Biology. 31: 207-214. PMID 7757303 DOI: 10.1007/Bf02639435 |
0.362 |
|
| 1995 |
Shawler DL, Dorigo O, Gjerset RA, Royston I, Sobol RE, Fakhrai H. Comparison of gene therapy with interleukin-2 gene modified fibroblasts and tumor cells in the murine ct-26 model of colorectal carcinoma Journal of Immunotherapy. 17: 201-208. PMID 7582256 DOI: 10.1097/00002371-199505000-00002 |
0.31 |
|
| 1995 |
Sobol R, Dorigo O, Shawler D, Lin H, Royston I, Fakhrai H. Immuno-gene therapy of rat glioma with TGF-β2 antisense and IL-2 gene modified tumor cells European Journal of Cancer. 31: S20. DOI: 10.1016/0959-8049(95)99891-3 |
0.323 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2019 |
Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 64-84. PMID 30659131 DOI: 10.6004/Jnccn.2019.0001 |
0.298 |
|
| 2011 |
Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu H, Song M, Dorigo O. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2373-84. PMID 21372221 DOI: 10.1158/1078-0432.Ccr-10-2289 |
0.298 |
|
| 1999 |
Dorigo O, Berek JS. Molecular strategies for treatment of ovarian cancer: Potential of immuno-gene therapy and correction of genetic defects Cme Journal of Gynecologic Oncology. 4: 125-129. |
0.297 |
|
| 2016 |
Morgan RJ, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, et al. Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 1134-63. PMID 27587625 DOI: 10.6004/Jnccn.2016.0122 |
0.296 |
|
| 2020 |
Shon DJ, Malaker SA, Pedram K, Yang E, Krishnan V, Dorigo O, Bertozzi CR. An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins. Proceedings of the National Academy of Sciences of the United States of America. PMID 32817557 DOI: 10.1073/Pnas.2012196117 |
0.294 |
|
| 2013 |
Masri WE, Hillerup C, Topka C, Santiskulvong C, Chiang A, Wu L, Rao J, Dorigo O. Abstract 1543: Tumor associated macrophages are associated with poor survival in epithelial ovarian cancer. Cancer Research. 73: 1543-1543. DOI: 10.1158/1538-7445.Am2013-1543 |
0.292 |
|
| 2015 |
Moughon D, He H, Schokrpur S, Jiang ZK, Yaqoob M, David J, Lin C, Iruela-Arispe ML, Dorigo O, Wu L. Macrophage Blockade Using CSF1R Inhibitors Reverses The Vascular Leakage Underlying Malignant Ascites In Late-Stage Epithelial Ovarian Cancer. Cancer Research. PMID 26471360 DOI: 10.1158/0008-5472.Can-14-3373 |
0.29 |
|
| 1997 |
Shawler D, Dorigo O, VanBeveren C, Bartholomew R, Fakhrai H, SObol R. Interleukin-2 (IL-2) gene therapy with allogeneic fibroblasts in the CT-26 model of murine colorectal carcinoma Oncology Reports. 4: 135-138. DOI: 10.3892/Or.4.1.135 |
0.288 |
|
| 2020 |
Ruscito I, Bellati F, Ray-Coquard I, Mirza MR, du Bois A, Gasparri ML, Costanzi F, De Marco MP, Nuti M, Caserta D, Pignata S, Dorigo O, Sehouli J, Braicu EI. Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. Cancer Treatment Reviews. 87: 102040. PMID 32485510 DOI: 10.1016/J.Ctrv.2020.102040 |
0.288 |
|
| 2015 |
Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, et al. Cervical Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 395-404; quiz 404. PMID 25870376 DOI: 10.6004/Jnccn.2015.0055 |
0.284 |
|
| 2016 |
Krishnan V, Rinker-Schaeffer C, Dorigo O. Omental macrophages: Drivers of ovarian cancer metastatic colonization Gynecologic Oncology. 141: 68. DOI: 10.1016/J.Ygyno.2016.04.197 |
0.284 |
|
| 2015 |
Minamimoto R, Karam A, Jamali M, Barkhodari A, Gambhir SS, Dorigo O, Iagaru A. Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging. PMID 26611425 DOI: 10.1007/S00259-015-3263-7 |
0.282 |
|
| 2020 |
Johnson S, Renz M, Wheeler L, Diver E, Dorigo O, Litkouhi B, Behbakht K, Howitt B, Karam A. Vulvar sarcoma outcomes by histologic subtype: a Surveillance, Epidemiology, and End Results (SEER) database review. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 32641392 DOI: 10.1136/Ijgc-2020-001516 |
0.281 |
|
| 1995 |
Sobol RE, Royston I, Fakhrai H, Shawler DL, Carson C, Dorigo O, Gjerset R, Gold DP, Koziol J, Mercola D, Van Beveren C, Wilson D. Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): A phase I study Human Gene Therapy. 6: 195-204. PMID 7734519 DOI: 10.1089/Hum.1995.6.2-195 |
0.276 |
|
| 1993 |
Herndier B, McGrath M, Abbey N, Wang HT, Ng V, Dorigo O, Kaplan L, Muller S, Kohler H. A non-lymphoma idiotype is indicative and predictive for B cell malignancies in AIDS Hybridoma. 12: 529-537. PMID 8300126 DOI: 10.1089/Hyb.1993.12.529 |
0.274 |
|
| 2019 |
Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, et al. Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 1374-1391. PMID 31693991 DOI: 10.6004/Jnccn.2019.0053 |
0.274 |
|
| 2014 |
Masghati S, Dorigo O, Santisvkulvong C. Abstract 3287: Mutational analysis of serous ovarian cancer using Ion Torrent sequencing Cancer Research. 74: 3287-3287. DOI: 10.1158/1538-7445.Am2014-3287 |
0.273 |
|
| 2018 |
Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, et al. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 170-199. PMID 29439178 DOI: 10.6004/Jnccn.2018.0006 |
0.269 |
|
| 2011 |
Dorigo O, Berek JS. Personalizing CA125 levels for ovarian cancer screening. Cancer Prevention Research (Philadelphia, Pa.). 4: 1356-9. PMID 21893498 DOI: 10.1158/1940-6207.Capr-11-0378 |
0.269 |
|
| 2020 |
Richardson MT, Routson S, Karam A, Dorigo O, Levy K, Renz M, Diver EJ. The role of asymptomatic screening in the detection of recurrent ovarian cancer. Gynecologic Oncology Reports. 33: 100595. PMID 32548232 DOI: 10.1016/J.Gore.2020.100595 |
0.264 |
|
| 2018 |
Dorigo O, Oza A, Tanyi J, Strauss J, Pejovic T, Ghamande S, Ghatage P, Villella J, Fiset S, MacDonald L, Torrey H, Weir G, Hrytsenko O, Stanford M, Newton R, et al. New clinical data from the DeCidE1 trial: Results on DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with advanced recurrent epithelial ovarian cancer Annals of Oncology. 29: x31. DOI: 10.1093/Annonc/Mdy487.018 |
0.264 |
|
| 2015 |
Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, et al. Uterine Sarcoma, Version 1.2016. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 1321-31. PMID 26553763 DOI: 10.6004/Jnccn.2015.0162 |
0.261 |
|
| 2008 |
Karam A, Berek JS, Stenson A, Rao J, Dorigo O. HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review. Gynecologic Oncology. 111: 568-71. PMID 18252264 DOI: 10.1016/J.Ygyno.2007.12.014 |
0.26 |
|
| 2014 |
Karam A, Dorigo O. Increased risk and pattern of secondary malignancies in patients with invasive extramammary Paget disease British Journal of Dermatology. 170: 661-671. PMID 24617434 DOI: 10.1111/Bjd.12635 |
0.259 |
|
| 2017 |
Dorigo O. Women's cancer: Advancing molecular and immunotherapy. Current Problems in Cancer. 41: 7. PMID 28366203 DOI: 10.1016/J.Currproblcancer.2017.02.004 |
0.256 |
|
| 1998 |
Dorigo O, Berek JS. Ovarian cancer gene therapy: Molecular scissors of the new millennium? Journal of Gynecologic Techniques. 4: 149-162. |
0.255 |
|
| 2020 |
Karam A, Dorigo O. Minimally Invasive Surgery for Gynecologic Cancers-A Cautionary Tale. Jama Oncology. PMID 32525507 DOI: 10.1001/Jamaoncol.2020.1617 |
0.253 |
|
| 2009 |
Lipshutz GS, Mihara N, Wong R, Wallace WD, Allen-Auerbach M, Dorigo O, Rao PN, Pham PCT, Pham PTT. Death from metastatic donor-derived ovarian cancer in a male kidney transplant recipient American Journal of Transplantation. 9: 428-432. PMID 19178417 DOI: 10.1111/J.1600-6143.2008.02507.X |
0.253 |
|
| 2015 |
Elvin J, Wang K, Ali S, Chmielecki J, Stephens P, Dorigo O, Ross J. Comprehensive genomic profiling of advanced stage endometrioid endometrial adenocarcinomas (EEAC) reveals differences associated with CTNNB1 mutation status and a high frequency of clinically relevant genomic alterations Gynecologic Oncology. 137: 65-66. DOI: 10.1016/J.Ygyno.2015.01.154 |
0.25 |
|
| 2022 |
Chow S, Dorigo O. Monocytes - A Promising New TRAIL in Ovarian Cancer Cell Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36383129 DOI: 10.1158/1078-0432.CCR-22-2877 |
0.248 |
|
| 2012 |
Gomez C, Lee S, Kupelian P, Dorigo O, Karam A, Konecny G, Steinberg M, Demanes D, Kamrava M. Combined Chemotherapy and Radiation Results in Improved Outcomes in High-Risk Endometrial Cancer Patients International Journal of Radiation Oncology*Biology*Physics. 84: S450. DOI: 10.1016/J.Ijrobp.2012.07.1192 |
0.247 |
|
| 2019 |
Chanana AM, Krishnan V, Tallapragada S, Dorigo O. Abstract 1964: C-C chemokine receptor type 1 is a prognostic indicator in ovarian cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1964 |
0.242 |
|
| 2014 |
He H, Moughon DL, Hillerup C, ElMasri W, Wu L, Dorigo O. The role of tumor associated macrophages in ovarian cancer Gynecologic Oncology. 135: 385. DOI: 10.1016/J.Ygyno.2014.07.016 |
0.24 |
|
| 2012 |
Brunette L, Galliano G, Rao J, Dorigo O. Dual staining for p16/KI67 combined with colposcopy as a predictor of high grade dysplasia in patients with atypical squamous cells of undetermined significance/HPV positive pap smears Gynecologic Oncology. 127: S11. DOI: 10.1016/J.Ygyno.2012.07.030 |
0.237 |
|
| 2021 |
Qian J, LeSavage BL, Hubka KM, Ma C, Natarajan S, Eggold JT, Xiao Y, Fuh KC, Krishnan V, Enejder A, Heilshorn SC, Dorigo O, Rankin EB. Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling. The Journal of Clinical Investigation. 131. PMID 34396988 DOI: 10.1172/JCI146186 |
0.235 |
|
| 1990 |
Tillmanns H, Neumann FJ, Parekh N, Zimmermann R, Tiefenbacher C, Dorigo O, Steinhausen M, Kübler W. Microcirculation in the hypertrophic and ischemic heart European Journal of Clinical Pharmacology. 39. PMID 2148154 DOI: 10.1007/Bf01409200 |
0.232 |
|
| 2012 |
Penner KR, Dorigo O, Aoyama C, Ostrzega N, Balzer BL, Rao J, Walsh CS, Cass I, Holschneider CH. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecologic Oncology. 124: 542-8. PMID 22079678 DOI: 10.1016/J.Ygyno.2011.11.004 |
0.231 |
|
| 2000 |
Ghosh K, Dorigo O, Bristow R, Berek J. A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction: A case report and review of the literature Journal of the American College of Surgeons. 191: 212-215. PMID 10945368 DOI: 10.1016/S1072-7515(00)00350-1 |
0.23 |
|
| 2020 |
Kamat K, Krishnan V, Berek JS, Dorigo O. Cell-based immunotherapy in gynecologic malignancies. Current Opinion in Obstetrics & Gynecology. PMID 33278077 DOI: 10.1097/GCO.0000000000000676 |
0.227 |
|
| 2019 |
Schaar B, Krishnan V, Tallapragada S, Chanana A, Dorigo O. Cell-based immunotherapy in gynecologic malignancies. Current Opinion in Obstetrics & Gynecology. 31: 43-48. PMID 30540582 DOI: 10.1097/GCO.0000000000000518 |
0.227 |
|
| 2017 |
Porter JB, Rosenthal EL, Winget M, Smith AS, Seshadri SB, Vetteth Y, Kiamanesh EF, Badwe A, Advani RH, Buyyounouski MK, Coutre S, Dirbas F, Divi V, Dorigo O, Ganjoo KN, et al. Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center. Journal of Oncology Practice. JOP2017021139. PMID 28727487 DOI: 10.1200/Jop.2017.021139 |
0.224 |
|
| 2019 |
Renz M, Diver E, English D, Kidd E, Dorigo O, Karam A. Sentinel lymph node biopsies in endometrial cancer - practice patterns among Gynecologic Oncologists in the United States. Journal of Minimally Invasive Gynecology. PMID 30980995 DOI: 10.1016/J.Jmig.2019.04.006 |
0.224 |
|
| 2014 |
Masghati S, Nosratian M, Dorigo O. Anti-N-methyl-aspartate receptor encephalitis in identical twin sisters: role for oophorectomy. Obstetrics and Gynecology. 123: 433-5. PMID 24413237 DOI: 10.1097/Aog.0000000000000078 |
0.222 |
|
| 2008 |
Penner K, Dorigo O, Walsh C, Cass I, Holschneider C. Multi-institutional study identifying predictors of response to progestin treatment of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma Gynecologic Oncology. 111: 379. DOI: 10.1016/J.Ygyno.2008.07.076 |
0.222 |
|
| 2012 |
Karam A, Dorigo O. Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease. Gynecologic Oncology. 125: 346-51. PMID 22293043 DOI: 10.1016/J.Ygyno.2012.01.032 |
0.222 |
|
| 2016 |
Nosratian-Baskovic M, Tan B, Folkins A, Chisholm KM, Dorigo O. Hemophagocytic lymphohistiocytosis as a paraneoplastic syndrome associated with ovarian dysgerminoma. Gynecologic Oncology Reports. 17: 38-41. PMID 27354999 DOI: 10.1016/J.Gore.2016.05.013 |
0.22 |
|
| 2011 |
Karam A, Dorigo O. Risk of second malignancies following extramammary Paget's disease Gynecologic Oncology. 120: S119-S120. DOI: 10.1016/J.Ygyno.2010.12.288 |
0.219 |
|
| 1995 |
Sobol RE, Fakhrai H, Shawler D, Gjerset R, Dorigo O, Carson C, Khaleghi T, Koziol J, Shiftan TA, Royston I. Interleukin-2 gene therapy in a patient with glioblastoma Gene Therapy. 2: 164-167. PMID 7719933 |
0.215 |
|
| 2022 |
Kamat K, Krishnan V, Dorigo O. Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer. British Journal of Cancer. PMID 35750747 DOI: 10.1038/s41416-022-01887-3 |
0.211 |
|
| 2021 |
Lang SM, Dorigo O. Cell-based immunotherapies in gynecologic cancers. Current Opinion in Obstetrics & Gynecology. 34: 10-14. PMID 34967809 DOI: 10.1097/GCO.0000000000000760 |
0.203 |
|
| 2019 |
Gershenson D, Miller A, Brady W, Paul J, Carty K, Rodgers W, Millan D, Coleman R, Moore K, Banerjee S, Connolly K, Secord A, O’Malley D, Dorigo O, Gaillard S, et al. A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer Annals of Oncology. 30: v897-v898. DOI: 10.1093/Annonc/Mdz394.058 |
0.201 |
|
| 2020 |
Krishnan V, Tallapragada S, Schaar B, Kamat K, Chanana AM, Zhang Y, Patel S, Parkash V, Rinker-Schaeffer C, Folkins AK, Rankin EB, Dorigo O. Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1. Communications Biology. 3: 524. PMID 32963283 DOI: 10.1038/s42003-020-01246-z |
0.199 |
|
| 2014 |
Westhoff G, Dorigo O, Berek J, Karam A. Vaginal and vulvar sarcomas: A population based review of incidence, treatment and outcomes Gynecologic Oncology. 135: 393-394. DOI: 10.1016/J.Ygyno.2014.07.038 |
0.198 |
|
| 1998 |
DORIGO O, HORTON H, HERNANDEZ P, ANDERSON D, NORMAN J, PARKER S, BEREK J. Gene therapy of ovarian cancer using intraperitoneal injection of IL-2 plasmid DNA Journal of the Society For Gynecologic Investigation. 5: 81A-81A. DOI: 10.1016/S1071-5576(97)86244-2 |
0.196 |
|
| 2021 |
Eggold JT, Chow S, Melemenidis S, Wang J, Natarajan S, Loo PE, Manjappa R, Viswanathan V, Kidd EA, Engleman E, Dorigo O, Loo BW, Rankin EB. Abdominopelvic FLASH Irradiation Improves PD-1 Immune Checkpoint Inhibition in Preclinical Models of Ovarian Cancer. Molecular Cancer Therapeutics. PMID 34866044 DOI: 10.1158/1535-7163.MCT-21-0358 |
0.189 |
|
| 2021 |
Moon AS, Dorigo O. Long-term efficacy of megestrol acetate and tamoxifen in a recurrent adult granulosa cell tumor of the ovary. Gynecologic Oncology Reports. 36: 100770. PMID 34013014 DOI: 10.1016/j.gore.2021.100770 |
0.188 |
|
| 2019 |
Levinson K, Dorigo O, Rubin K, Moore K. Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 39: e126-e140. PMID 31099679 DOI: 10.1200/EDBK_237967 |
0.187 |
|
| 1993 |
Gortner L, Pohlandt F, Bartmann P, Terinde R, Versmold H, Dorigo O. Short term outcome in infants by birth weights < 1750 g born to mothers by HELLP syndrome Journal of Perinatal Medicine. 20: 25-28. PMID 1608020 DOI: 10.1515/Jpme.1992.20.1.25 |
0.185 |
|
| 2015 |
Judy AE, Lyell DJ, Druzin ML, Dorigo O. Disseminated Intravascular Coagulation Complicating the Conservative Management of Placenta Percreta. Obstetrics and Gynecology. 126: 1016-8. PMID 26132459 DOI: 10.1097/Aog.0000000000000960 |
0.185 |
|
| 2007 |
Dorigo O, Berek JS. CA125: megadaltons of novel opportunities. Gynecologic Oncology. 104: 505-7. PMID 17306691 DOI: 10.1016/J.Ygyno.2007.01.035 |
0.183 |
|
| 1992 |
Tillmanns H, Neumann FJ, Waas W, Mall G, Parekh N, Tiefenbacher C, Dorigo O, Zimmermann R, Dart AM, Steinhausen M, Kubler W. New techniques for the study of the coronary microcirculation: Importance of measurements of coronary flow reserve in the clinical setting Coronary Artery Disease. 3: 586-592. DOI: 10.1097/00019501-199207000-00007 |
0.179 |
|
| 2022 |
Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, Trillsch F, Mustea A, Kreuzinger C, Gourley C, Gabra H, Taube ET, Dorigo O, Horst D, et al. Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium. Annals of Surgical Oncology. PMID 36085390 DOI: 10.1245/s10434-022-12459-3 |
0.173 |
|
| 2017 |
Koh WJ, Greer BE, Abu-Rustum NR, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, et al. Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 92-120. PMID 28040721 |
0.172 |
|
| 2020 |
Chow S, Berek JS, Dorigo O. Development of Therapeutic Vaccines for Ovarian Cancer. Vaccines. 8. PMID 33167428 DOI: 10.3390/vaccines8040657 |
0.172 |
|
| 2019 |
Diver E, Dorigo O, Berek J. ASCO 2019 meeting review. Journal of Gynecologic Oncology. 30: e107. PMID 31328469 DOI: 10.3802/Jgo.2019.30.E107 |
0.172 |
|
| 2020 |
Levy K, Natarajan S, Wang J, Chow S, Eggold JT, Loo PE, Manjappa R, Melemenidis S, Lartey FM, Schüler E, Skinner L, Rafat M, Ko R, Kim A, H Al-Rawi D, ... ... Dorigo O, et al. Abdominal FLASH irradiation reduces radiation-induced gastrointestinal toxicity for the treatment of ovarian cancer in mice. Scientific Reports. 10: 21600. PMID 33303827 DOI: 10.1038/s41598-020-78017-7 |
0.165 |
|
| 2023 |
Hui C, Mendoza MG, Snyder J, Dorigo O, Litkouhi B, Renz M, Karam A, Devereaux K, Howitt BE, Kidd EA. Adjuvant radiation therapy in early-stage endometrial cancer with abnormal beta-catenin expression is associated with improved local control. Gynecologic Oncology. 174: 42-48. PMID 37149904 DOI: 10.1016/j.ygyno.2023.04.018 |
0.164 |
|
| 2023 |
Dorigo O, Oza AM, Pejovic T, Ghatage P, Ghamande S, Provencher D, MacDonald LD, Torrey H, Kaliaperumal V, Ebrahimizadeh W, Hirsch HA, Bramhecha Y, Villella J, Fiset S. Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase 2 trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37126016 DOI: 10.1158/1078-0432.CCR-22-2595 |
0.163 |
|
| 2021 |
Kassuhn W, Klein O, Darb-Esfahani S, Lammert H, Handzik S, Taube ET, Schmitt WD, Keunecke C, Horst D, Dreher F, George J, Bowtell DD, Dorigo O, Hummel M, Sehouli J, et al. Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging. Cancers. 13. PMID 33806030 DOI: 10.3390/cancers13071512 |
0.16 |
|
| 2021 |
Devereaux KA, Weiel JJ, Pors J, Steiner DF, Ho C, Charu V, Suarez CJ, Renz M, Diver E, Karam A, Litkouhi B, Dorigo O, Kidd EA, Yang EJ, Folkins AK, et al. Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 34743187 DOI: 10.1038/s41379-021-00963-y |
0.158 |
|
| 2022 |
Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, Trillsch F, Mustea A, Kreuzinger C, Gourley C, Gabra H, Taube ET, Dorigo O, Horst D, et al. ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium. Annals of Surgical Oncology. 30: 46-47. PMID 36335272 DOI: 10.1245/s10434-022-12681-z |
0.145 |
|
| 2022 |
Malaker SA, Riley NM, Shon DJ, Pedram K, Krishnan V, Dorigo O, Bertozzi CR. Revealing the human mucinome. Nature Communications. 13: 3542. PMID 35725833 DOI: 10.1038/s41467-022-31062-4 |
0.145 |
|
| 2022 |
Keunecke C, Kulbe H, Dreher F, Taube ET, Chekerov R, Horst D, Hummel M, Kessler T, Pietzner K, Kassuhn W, Heitz F, Muallem MZ, Lang SM, Vergote I, Dorigo O, et al. Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer. Gynecologic Oncology. PMID 35738917 DOI: 10.1016/j.ygyno.2022.06.010 |
0.142 |
|
| 1999 |
Horton HM, Dorigo O, Hernandez P, Anderson D, Berek JS, Parker SE. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile Journal of Immunology. 163: 6378-6385. PMID 10586027 |
0.138 |
|
| 2021 |
Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Aghajanian C, Konecny GE, O'Malley DM, Leary A, Provencher D, Welch S, Chen LM, Wahner Hendrickson AE, ... ... Dorigo O, et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nature Communications. 12: 2487. PMID 33941784 DOI: 10.1038/s41467-021-22582-6 |
0.133 |
|
| 2006 |
Dorigo O, Berek JS. Cancer genetics Clinical Gynecology. 739-749. DOI: 10.1016/B978-0-443-06691-7.50056-X |
0.131 |
|
| 2021 |
Rahimy E, Usoz M, von Eyben R, Fujimoto D, Watanabe D, Karam A, Jairam-Thodla A, Mills M, Dorigo O, Diver EJ, Teng N, English D, Kidd E. Phase II trial evaluating efficacy of a Fitbit program for improving the health of endometrial cancer survivors. Gynecologic Oncology. PMID 33551199 DOI: 10.1016/j.ygyno.2021.01.033 |
0.125 |
|
| 1991 |
Wachter I, Anthuber C, Dorigo O, Habler O. Granulosa cell tumors in children and juvenile Archives of Gynecology and Obstetrics. 250: 444-445. |
0.118 |
|
| 2024 |
Somasegar S, Reddy RA, Chow S, Dorigo O, Renz M, Karam A. Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis. Gynecologic Oncology. 184: 190-197. PMID 38330833 DOI: 10.1016/j.ygyno.2024.01.034 |
0.111 |
|
| 2022 |
Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, Millan D, Coleman RL, Moore KN, Banerjee S, Connolly K, Secord AA, O'Malley DM, Dorigo O, Gaillard S, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet (London, England). 399: 541-553. PMID 35123694 DOI: 10.1016/S0140-6736(21)02175-9 |
0.111 |
|
| 2023 |
Beshar I, Moon AS, Darji H, Liu C, Jennings MT, Dorigo O, Litkouhi B, Diver EJ, Karam AK, Howitt BE, Renz M. Aberrant nuclear β-catenin distribution does not prognosticate recurrences of endometrioid endometrial cancers - A retrospective single-institutional study. Gynecologic Oncology. 179: 85-90. PMID 37944330 DOI: 10.1016/j.ygyno.2023.10.025 |
0.107 |
|
| 2022 |
Reddy RA, Moon AS, Chow S, Heilbroner L, Howitt B, Diver E, Dorigo O, Litkouhi B, Renz M, Karam A. Technetium Tc 99m tilmanocept fails to detect sentinel lymph nodes in endometrial cancer. Gynecologic Oncology Reports. 43: 101054. PMID 35958955 DOI: 10.1016/j.gore.2022.101054 |
0.103 |
|
| 2012 |
Fekete M, Santiskulvong C, Eng C, Dorigo O. Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells. Anticancer Research. 32: 445-52. PMID 22287731 |
0.099 |
|
| 2015 |
Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, et al. Cervical cancer, version 2.2015: Featured updates to the NCCN guidelines featured updates to the NCCN guidelines Jnccn Journal of the National Comprehensive Cancer Network. 13: 395-404. |
0.098 |
|
| 1995 |
Muller S, Brams P, Collins D, Dorigo O, Wang HT, Kohler H. Apoptosis of CD4+ and CD8+ cells from HIV-1-infected individuals: Role of antiidiotypic antibodies Vaccine Research. 4: 229-238. |
0.095 |
|
| 2022 |
Kibbi N, Owen JL, Worley B, Wang JX, Harikumar V, Downing MB, Aasi SZ, Aung PP, Barker CA, Bolotin D, Bordeaux JS, Cartee TV, Chandra S, Cho NL, Choi JN, ... ... Dorigo O, et al. Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. Jama Oncology. PMID 35050310 DOI: 10.1001/jamaoncol.2021.7148 |
0.076 |
|
| 2011 |
Karam A, Dorigo O. Treatment and outcome of patients with invasive extramammary Paget's disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5043. PMID 28023696 DOI: 10.1200/jco.2011.29.15_suppl.5043 |
0.075 |
|
| 2023 |
Hui C, Mendoza MG, von Eyben R, Dorigo O, Litkouhi B, Renz M, Karam A, Hammer PM, Howitt BE, Kidd E. Does lymph node assessment change the prognostic significance of substantial LVSI and p53 status in endometrial endometrioid carcinoma? Gynecologic Oncology. 177: 150-156. PMID 37696217 DOI: 10.1016/j.ygyno.2023.09.001 |
0.072 |
|
| 1993 |
Tillmanns H, Neumann FJ, Tiefenbacher C, Dorigo O, Parekh N, Waas W, Zimmermann R, Steinhausen M, Kuebler W. Activation of neutrophils in the microvasculature of the ischaemic and reperfused myocardium European Heart Journal. 14: 82-86. PMID 8293784 |
0.055 |
|
| 2016 |
Machado ACZ, Dorigo OF, Carneiro RMDG, De Araújo Filho JV. Meloidogyne luci, a new infecting nematode species on common bean fields at Paraná State, Brazil Helminthologia (Poland). 53: 207-210. DOI: 10.1515/helmin-2016-0014 |
0.054 |
|
| 2011 |
Penner K, Cass I, Walsh C, Aoyama C, Rao J, Balzer B, Ostrzega N, Dorigo O, Holschneider C. Endometrial intraepithelial neoplasia vs. World Health Organization classification of endometrial hyperplasia does not improve reliability of diagnosis or prediction of outcome in premenopausal women with preinvasive endometrial pathology undergoing progestin treatment Gynecologic Oncology. 123: 430-431. DOI: 10.1016/j.ygyno.2011.07.042 |
0.053 |
|
| 2015 |
Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, et al. Uterine sarcoma, version 1.2016: Featured updates to the NCCN Guidelines Jnccn Journal of the National Comprehensive Cancer Network. 13: 1321-1331. |
0.047 |
|
| 2014 |
Machado ACZ, Dorigo OF, Boss A, Tironi P. First report of Meloidogyne javanica parasitizing duboisia sp. In Paraná state, Brazil Plant Disease. 98: 1745. DOI: 10.1094/PDIS-06-14-0649-PDN |
0.043 |
|
| 2016 |
Dadazio TS, da Silva SA, Dorigo OF, Wilcken SRS, Machado ACZ. Host-Parasite Relationships in Root-Knot Disease Caused by Meloidogyne inornata in Common Bean (Phaseolus vulgaris) Journal of Phytopathology. DOI: 10.1111/jph.12494 |
0.04 |
|
| 2014 |
Machado ACZ, Silva SA, Dorigo OF, Riede CR, Garbuglio DD. Phenotypic variability and response of Brazilian oat genotypes to different species of root-knot and root-lesion nematodes European Journal of Plant Pathology. 141: 111-117. DOI: 10.1007/s10658-014-0529-z |
0.035 |
|
| 2005 |
Schwarz S, Dorigo O, Wegner F, Gill J, Labarca C, Berk A, Lester H, Schwarz J. Verstärkte dopaminerge Degeneration durch die nigrale Applikation von CRE-exprimierenden helper-dependent-Adenoviren in knock-in-Mäusen mit überempfindlichen nikotinergen alpha4-Rezeptoren Aktuelle Neurologie. 32. DOI: 10.1055/s-2005-866704 |
0.033 |
|
| 2009 |
Cardoso JD, Gomes DF, Goes KCGP, Fonseca NdS, Dorigo OF, Hungria M, Andrade DS. Relationship between total nodulation and nodulation at the root crown of peanut, soybean and common bean plants Soil Biology and Biochemistry. 41: 1760-1763. DOI: 10.1016/J.Soilbio.2009.05.008 |
0.033 |
|
| 2015 |
Ito DS, Silva SA, Dorigo OF, Machado ACZ, Sera GH. First report of Meloidogyne javanica on Tephrosia vogelii in Brazil Plant Disease. 99: 1285. DOI: 10.1094/PDIS-11-14-1160-PDN |
0.027 |
|
| 2013 |
Machado ACZ, Dorigo OF, Mattei D. First report of the root knot nematode, Melodogyne inornata, on common bean in Paraná State, Brazil Plant Disease. 97: 431. DOI: 10.1094/PDIS-09-12-0832-PDN |
0.015 |
|
| 1990 |
Tillmanns H, Neumann FJ, Parekh N, Dorigo O, Tiefenbacher C, Zimmermann R, Steinhausen M, Kubler W. Pharmacologic effects on coronary microvessels during myocardial ischaemia European Heart Journal. 11: 10-15. PMID 2364953 |
0.015 |
|
| 2013 |
MacHado ACZ, Silva SA, Dorigo OF, Mattei D. Meloidogyne javanica and M. arenaria on calla (Zantedeschia aethiopica) in Brazil Australasian Plant Disease Notes. 8: 131-132. DOI: 10.1007/s13314-013-0114-x |
0.012 |
|
| 1997 |
Dorigo O, Berek JS. The Gurski/Steller Article Reviewed Oncology. 11: 1743-1744. |
0.011 |
|
| 1993 |
Römisch M, Bauer F, Daponte A, Meier W, Dorigo O, Eiermann W. Lymphocytensubpopulationen gynäkologischer Malignompatientinnen in Korrelation zu bekannten Prognosefaktoren und als Verlaufsparameter unter Cytokintherapie Archives of Gynecology and Obstetrics. 254: 1091-1093. DOI: 10.1007/BF02266320 |
0.01 |
|
| 1993 |
Dorigo O, Meier W, Scheidel P, Hepp H. Wertigkeit der Darmresektion und der präoperativen Koloskopie beim Ovarialkarzinom Archives of Gynecology and Obstetrics. 254: 966-968. DOI: 10.1007/BF02266259 |
0.01 |
|
| Hide low-probability matches. |